Am Horizont: selektiver Neurokinin-1,3-Rezeptor-Antagonist Elinzanetant
Crossref DOI link: https://doi.org/10.1007/s41975-024-00372-9
Published Online: 2024-11-06
Published Print: 2024-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Stute, Petra
Funding for this research was provided by:
University of Bern
Text and Data Mining valid from 2024-11-06
Version of Record valid from 2024-11-06
Article History
Accepted: 18 October 2024
First Online: 6 November 2024
Interessenkonflikt
: P. Stute hat an Advisory Boards der Firmen Astellas und Bayer teilgenommen.